Linefor (Pregabalin)

Pregabalin binds to the α2‑δ subunit of voltage‑gated calcium channels in the central nervous system. This binding limits calcium entry into nerve terminals, decreasing the release of excitatory neurotransmitters such as glutamate, norepinephrine and substance P, thereby reducing neuronal hyper‑excitability and pain signaling.

The dose of Linefor is individualized by the prescribing clinician based on the specific indication, patient age, renal function and therapeutic response. Starting doses are typically low and may be titrated upward as needed, but the exact regimen must be determined by a qualified healthcare professional.

Data on pregabalin use in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To order Linefor, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

The most common alternative to pregabalin is gabapentin, another GABA analog. Both drugs share a similar mechanism but pregabalin generally has higher bioavailability, a more predictable pharmacokinetic profile, and may achieve therapeutic effect at lower doses. Choice between them depends on individual response, tolerability and prescriber preference.

Linefor should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use it after the expiry date printed on the label. No special refrigeration is required for this oral formulation.

Linefor is taken orally, usually with or without food. Tablets should be swallowed whole with a glass of water and not crushed, chewed, or split unless specifically instructed by a healthcare professional. The exact timing and frequency are determined by the prescriber based on the therapeutic indication.

Serious risks associated with Linefor include the potential for suicidal thoughts or behavior, angioedema (swelling of the face, lips, tongue or throat), severe skin reactions such as Stevens‑Johnson syndrome, and respiratory depression when combined with other central nervous system depressants. Patients should seek immediate medical attention if any of these occur.

Linefor is contraindicated in individuals with known hypersensitivity to pregabalin or any of its excipients. Patients with severe renal impairment (creatinine clearance <30 mL/min) should avoid use unless dose adjustments are made under specialist supervision. Caution is also advised for those with a history of substance misuse.